Sunday, February 18, 2018
 
 
Company News: Page (1) of 1 - 01/17/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple MyelomaResults Support Ear...
(January 17, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:Manufacturing,Sales,Applications,Suppliers,Manufacturing/Production,Marketing,Insurance,Shipping & Receiving,Manufacturing,Sales & Marketing,Security,Business Issues,Administration,Legal,Standards,Management,Human Resources,Sales,Human Resources,Sales,USA,Korea,IT (Information Technology),Security,Medicine,
Related Sites: DMN Newswire ,   itbusinessnet.com ,   IBN - Business ,   IBN - ProductivityApps ,   IBN - Security ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines